PDCD1 and melanoma: In contrast, inhibition of the PD-1/PD-L1 pathway by administration of the checkpoint inhibitors pembrolizumab or nivolumab during cancer immunotherapy caused a higher incidence of acute interstitial nephritis in patients with melanoma or lung cancer45.